Literature DB >> 10449196

Inhibition of tumor necrosis factor-alpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin.

F Mancini1, C M Toro, M Mabilia, M Giannangeli, M Pinza, C Milanese.   

Abstract

Suramin, a symmetrical polysulfonated urea derivative, promotes the dissociation of trimeric human tumor necrosis factor-alpha (TNF-alpha) into biologically inactive subunits and prevents the interaction of TNF-alpha with its cellular receptors. The aim of this work was to identify compounds structurally related to suramin which inhibit the binding of TNF-alpha to its receptor. Molecular modeling studies were performed on suramin and TNF-alpha molecules and likely interaction sites were identified in the docked complex. On this basis, Evans blue, trypan blue, sulfonazo III, beryllon II, and 1,3,6-naphthalenetrisulfonic acid trisodium salt were identified as polysulfonated compounds endowed, to various extents, with the structural characteristics responsible for interaction with TNF-alpha. N,N-bis(3,5-di-tert-butylphenyl)-3,4,9,10-perylenedicarboximide was used as an unrelated structure. The capacity of these molecules to inhibit the binding of TNF-alpha with its receptor p55 was tested in vitro by means of a specific immunoenzymatic assay using suramin as reference compound. Evans blue and trypan blue inhibited TNF-alpha/p55 binding with an IC50 of 0.75 and 1.00 mM, respectively (suramin IC50: 0.65 mM); no effect was observed with the other molecules. Molecular modeling analyses on Evans blue and trypan blue docked into the TNF-alpha molecule support these experimental results by demonstrating that these compounds share with suramin a similar binding mode to TNF-alpha. The results of this work provide a new insight into and useful hints for the design of new chemical entities endowed with a potent and selective activity on TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449196     DOI: 10.1016/s0006-2952(99)00150-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.

Authors:  P H Carter; P A Scherle; J K Muckelbauer; M E Voss; R Q Liu; L A Thompson; A J Tebben; K A Solomon; Y C Lo; Z Li; P Strzemienski; G Yang; N Falahatpisheh; M Xu; Z Wu; N A Farrow; K Ramnarayan; J Wang; D Rideout; V Yalamoori; P Domaille; D J Underwood; J M Trzaskos; S M Friedman; R C Newton; C P Decicco; J A Muckelbauer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

2.  Structure-based discovery of natural-product-like TNF-α inhibitors.

Authors:  Daniel Shiu-Hin Chan; Ho-Man Lee; Fang Yang; Chi-Ming Che; Catherine C L Wong; Ruben Abagyan; Chung-Hang Leung; Dik-Lung Ma
Journal:  Angew Chem Int Ed Engl       Date:  2010-03-16       Impact factor: 15.336

Review 3.  TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.

Authors:  Yun Song; Peter Buchwald
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

4.  Fullerenes and their derivatives as inhibitors of tumor necrosis factor-α with highly promoted affinities.

Authors:  Gaoyin Wu; Xuejiao J Gao; Joonkyung Jang; Xingfa Gao
Journal:  J Mol Model       Date:  2016-06-18       Impact factor: 1.810

5.  Identification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFα through combined in silico/in vitro/in vivo screening.

Authors:  Hadley Mouhsine; Hélène Guillemain; Gabriel Moreau; Najla Fourati; Chouki Zerrouki; Bruno Baron; Lucille Desallais; Patrick Gizzi; Nesrine Ben Nasr; Julie Perrier; Rojo Ratsimandresy; Jean-Louis Spadoni; Hervé Do; Patrick England; Matthieu Montes; Jean-François Zagury
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

6.  Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).

Authors:  Georgia Melagraki; Evangelos Ntougkos; Vagelis Rinotas; Christos Papaneophytou; Georgios Leonis; Thomas Mavromoustakos; George Kontopidis; Eleni Douni; Antreas Afantitis; George Kollias
Journal:  PLoS Comput Biol       Date:  2017-04-20       Impact factor: 4.475

7.  Design, Synthesis, and Evaluation of Dihydrobenzo[cd]indole-6-sulfonamide as TNF-α Inhibitors.

Authors:  Xiaobing Deng; Xiaoling Zhang; Bo Tang; Hongbo Liu; Qi Shen; Ying Liu; Luhua Lai
Journal:  Front Chem       Date:  2018-04-04       Impact factor: 5.221

8.  In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).

Authors:  Georgia Melagraki; Evangelos Ntougkos; Dimitra Papadopoulou; Vagelis Rinotas; Georgios Leonis; Eleni Douni; Antreas Afantitis; George Kollias
Journal:  Front Pharmacol       Date:  2018-07-25       Impact factor: 5.810

9.  Using a Consensus Docking Approach to Predict Adverse Drug Reactions in Combination Drug Therapies for Gulf War Illness.

Authors:  Rajeev Jaundoo; Jonathan Bohmann; Gloria E Gutierrez; Nancy Klimas; Gordon Broderick; Travis J A Craddock
Journal:  Int J Mol Sci       Date:  2018-10-26       Impact factor: 5.923

10.  Structure-Based Design, Synthesis and Bioactivity of a New Anti-TNFα Cyclopeptide.

Authors:  Mohannad Idress; Bruce F Milne; Gary S Thompson; Laurent Trembleau; Marcel Jaspars; Wael E Houssen
Journal:  Molecules       Date:  2020-02-19       Impact factor: 4.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.